The value of intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism and varying baseline parathyroid hormone levels.
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
02 11 2022
02 11 2022
Historique:
received:
06
07
2022
revised:
18
08
2022
accepted:
21
08
2022
entrez:
14
12
2022
pubmed:
15
12
2022
medline:
17
12
2022
Statut:
ppublish
Résumé
When applying intraoperative parathyroid hormone monitoring (IOPTH) to patients with primary hyperparathyroidism (PHPT), there are established criteria predicting biochemical cure in patients with basal parathyroid hormone (PTH) levels in the medium range (100-400 pg/ml); however, there is a challenge concerning patients with low (less than 100 pg/ml) or high (more than 400 pg/ml) basal PTH levels. The aim of this study was to investigate the value of the 'Vienna criterion' applied during IOPTH in patients with PHPT and various basal PTH concentrations. Consecutive patients between 1999-2009 with a biochemical diagnosis of PHPT who underwent surgical parathyroidectomy were included. Based on preoperative PTH levels they were divided into three groups: group 1 (low) (<100 pg/ml), group 2 (medium) (100-400 pg/ml) and group 3 (high) (>400 pg/ml) basal PTH. PTH was measured at the start of the operation, when the gland was excised and then at 5, 10 and 15 min after. Calcium and PTH levels were measured at 7 days and 12 months postoperatively. Sensitivity, specificity, positive and negative predictive value, as well as accuracy of IOPTH were calculated for the different groups postoperatively. 675 patients with PHPT were analysed. Sensitivity and specificity were 83.7 per cent and 66.7 per cent in group 1 (n = 187), 90.7 per cent and 69.2 per cent in group 2 (n = 433), and 94.4 per cent and 100 per cent in group 3 (n = 55) to predict cure. Preoperative creatinine (p = 0.002) showed significant statistical difference between the groups but was not related to intraoperative PTH decline. At 12 months follow-up normocalcaemia was documented in 98.9 per cent in group 1, 99.0 per cent group 2, and 98.0 per cent of group 3 patients. Normocalcaemia was predicted intraoperatively by applying the 'Vienna criterion' in 98 to 100 per cent and was confirmed after 12 months follow-up in up to 99.0 per cent of patients. Low specificity and a high false-negative rate in patients with low basal PTH show that other criteria might be better suited for this group.
Sections du résumé
BACKGROUND
When applying intraoperative parathyroid hormone monitoring (IOPTH) to patients with primary hyperparathyroidism (PHPT), there are established criteria predicting biochemical cure in patients with basal parathyroid hormone (PTH) levels in the medium range (100-400 pg/ml); however, there is a challenge concerning patients with low (less than 100 pg/ml) or high (more than 400 pg/ml) basal PTH levels. The aim of this study was to investigate the value of the 'Vienna criterion' applied during IOPTH in patients with PHPT and various basal PTH concentrations.
METHODS
Consecutive patients between 1999-2009 with a biochemical diagnosis of PHPT who underwent surgical parathyroidectomy were included. Based on preoperative PTH levels they were divided into three groups: group 1 (low) (<100 pg/ml), group 2 (medium) (100-400 pg/ml) and group 3 (high) (>400 pg/ml) basal PTH. PTH was measured at the start of the operation, when the gland was excised and then at 5, 10 and 15 min after. Calcium and PTH levels were measured at 7 days and 12 months postoperatively. Sensitivity, specificity, positive and negative predictive value, as well as accuracy of IOPTH were calculated for the different groups postoperatively.
RESULTS
675 patients with PHPT were analysed. Sensitivity and specificity were 83.7 per cent and 66.7 per cent in group 1 (n = 187), 90.7 per cent and 69.2 per cent in group 2 (n = 433), and 94.4 per cent and 100 per cent in group 3 (n = 55) to predict cure. Preoperative creatinine (p = 0.002) showed significant statistical difference between the groups but was not related to intraoperative PTH decline. At 12 months follow-up normocalcaemia was documented in 98.9 per cent in group 1, 99.0 per cent group 2, and 98.0 per cent of group 3 patients.
CONCLUSION
Normocalcaemia was predicted intraoperatively by applying the 'Vienna criterion' in 98 to 100 per cent and was confirmed after 12 months follow-up in up to 99.0 per cent of patients. Low specificity and a high false-negative rate in patients with low basal PTH show that other criteria might be better suited for this group.
Identifiants
pubmed: 36515670
pii: 6901339
doi: 10.1093/bjsopen/zrac118
pmc: PMC9749480
pii:
doi:
Substances chimiques
Parathyroid Hormone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
JAMA Surg. 2016 Oct 1;151(10):959-968
pubmed: 27532368
Langenbecks Arch Surg. 2009 Sep;394(5):875-80
pubmed: 19440730
J Clin Endocrinol Metab. 1993 Mar;76(3):715-20
pubmed: 8445032
Surgery. 2011 Dec;150(6):1113-9
pubmed: 22136829
World J Surg. 2004 Dec;28(12):1287-92
pubmed: 15517474
Arch Surg. 2011 Mar;146(3):280-5
pubmed: 21422358
J Surg Res. 2020 Feb;246:139-144
pubmed: 31569035
Clin Endocrinol (Oxf). 2018 Jan;88(1):129-138
pubmed: 28906021
Langenbecks Arch Surg. 2009 Sep;394(5):843-9
pubmed: 19529957
Nephrol Dial Transplant. 2002 May;17(5):765-71
pubmed: 11981061
Arch Surg. 2001 Aug;136(8):945-9
pubmed: 11485536
World J Surg. 2016 Oct;40(10):2359-77
pubmed: 27094563
Ann Surg Oncol. 2017 Jul;24(7):1924-1934
pubmed: 27896505
Surgery. 2021 May;169(5):1152-1157
pubmed: 33423798
Clin Endocrinol (Oxf). 2013 Jun;78(6):935-41
pubmed: 23046058
Ann Surg Oncol. 2013 Dec;20(13):4205-11
pubmed: 23943034
Surgery. 2018 Jan;163(1):42-47
pubmed: 29128188
Eur J Endocrinol. 2018 Jan;178(1):1-9
pubmed: 28877925
Eur Surg. 2018;50(5):228-231
pubmed: 30294345
Am J Surg. 1994 Nov;168(5):466-8
pubmed: 7977975
Surgery. 2018 Mar;163(3):633-637
pubmed: 29273178
Surgery. 2008 Dec;144(6):989-93; discussion 993-4
pubmed: 19041008
Surgery. 2006 Dec;140(6):883-9; discussion 889-90
pubmed: 17188134
Ann Surg. 2004 May;239(5):704-8; discussion 708-11
pubmed: 15082975
Arch Surg. 2001 Jul;136(7):810-6
pubmed: 11448396
Laryngoscope. 2009 Jun;119(6):1100-5
pubmed: 19418534
Chirurg. 2010 Jul;81(7):636, 638-42
pubmed: 20549175
Am J Surg. 1991 Oct;162(4):299-302
pubmed: 1683177
Surgery. 2000 Dec;128(6):1029-34
pubmed: 11114639
Ann Surg Oncol. 2015 Mar;22(3):966-71
pubmed: 25245126
Langenbecks Arch Surg. 2013 Aug;398(6):881-6
pubmed: 23828733
Surgery. 2003 Dec;134(6):973-9; discussion 979-81
pubmed: 14668730
Am J Surg. 2009 Mar;197(3):284-90
pubmed: 19245902
Ann Surg Oncol. 2015 Aug;22(8):2707-13
pubmed: 25480411
Acta Med Port. 2017 Jun 30;30(6):485-492
pubmed: 28898616
J Clin Endocrinol Metab. 2004 Jul;89(7):3208-13
pubmed: 15240594
Thyroid. 2006 Mar;16(3):259-65
pubmed: 16571088
Surgery. 2007 Sep;142(3):398-404
pubmed: 17723893
J Clin Invest. 1931 Apr;10(1):187-219
pubmed: 16693966
Head Neck. 2018 Dec;40(12):2664-2669
pubmed: 30479056
Am J Surg. 2015 Mar;209(3):483-7
pubmed: 25556028
Langenbecks Arch Surg. 2009 Sep;394(5):799-809
pubmed: 19590891
Langenbecks Arch Surg. 2009 Sep;394(5):891-5
pubmed: 19396458
Surgery. 2017 Feb;161(2):493-498
pubmed: 27712879
World J Surg. 2011 Sep;35(9):2006-9
pubmed: 21713573
Langenbecks Arch Surg. 2007 Jul;392(4):427-30
pubmed: 17187286
BJS Open. 2018 May 28;2(6):364-370
pubmed: 30511037
Surgery. 2012 Dec;152(6):1008-15
pubmed: 23063313
Clin J Am Soc Nephrol. 2007 Nov;2(6):1283-305
pubmed: 17942777